Cardiac surgery market to reach over $4.4 billion by 2017

Jan 18 2011

According to a new report by iData Research (www.idataresearch.net), the leading global authority in medical device and pharmaceutical market research, percutaneous aortic valve replacement (PAVR) and percutaneous mitral valve repair (PMVR) devices are expected to enter the U.S. market in 2011 and grow to almost $1.3 billion by 2017. Adoption of these devices for treating mitral regurgitation, aortic stenosis and aortic insufficiency will fuel the overall U.S. cardiac surgery market to over $4.4 billion by 2017.  Companies such as Medtronic and Edwards Lifesciences are expected to be the first suppliers of PAVR and PMVR devices for the U.S. market.

"Approximately 1.2 million people in the U.S. have malfunctioning aortic valves and advances in diagnostic technologies, such as CT and MRI are increasing the diagnosis rates" says Dr. Kamran Zamanian, CEO of iData. "PAVR allows for aortic valve replacement without the need for open surgery, increasing patient safety and reducing recovery times. However the lack of long-term clinical data, complexity and high-cost of the procedure may limit initial adoption."

The report states that PAVR products by Medtronic and Edwards are available on the market in Europe, while U.S. clinical trials are currently underway. PMVR products by Evalve for the treatment of mitral regurgitation are also approved in Europe and pending FDA approval.

"Mitral valve disorders are usually diagnosed in patients over 65 and physicians are reluctant to perform open surgery if other comorbidities exist," says Dr. Zamanian. "PMVR procedures allow for a larger number of patients to be treated, leading to a CAGR of over 60% by 2017."

iData's report series on the U.S., European and Asian "Markets for Cardiac Surgery Devices" includes: tissue and mechanical heart valves, annuloplasty repair, PMVR, PAVR, ONCAB, OPCAB, endoscopic vessel-harvesting, cardiac ablation, transmyocardioal revascularization, intra-aortic balloons, artificial hearts, anastomosis-assist, ventricular-assist, PFO, ASD and VSD devices.

SOURCE iData Research Inc.